Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 11 (November)

1. Long-term outcome among men with conservatively treated localised prostate cancer.
   Br J Cancer, 95(9): 1186-94. [Abstract] [Full-text]
2. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
   J Natl Cancer Inst, 98(21): 1521-7. [Abstract] [Full-text]
3. Recreational physical activity and risk of prostate cancer: A prospective population-based study in Norway (the HUNT study).
   Int J Cancer, 119(12): 2943-7. [Abstract] [Full-text]
4. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
   Cancer Res, 66(21): 10613-20. [Abstract] [Full-text]
5. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
   Cancer Res, 66(21): 10594-602. [Abstract] [Full-text]
6. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens.
   Cancer Res, 66(21): 10513-6. [Abstract] [Full-text]
7. Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications.
   Cancer Res, 66(21): 10449-59. [Abstract] [Full-text]
8. Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk.
   Cancer Res, 66(21): 10302-7. [Abstract] [Full-text]
9. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
   Cancer Res, 66(21): 10242-6. [Abstract] [Full-text]
10. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy.
    J Androl, 27(6): 725-8. [Abstract] [Full-text]
11. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer.
    J Med Genet, 43(11): 863-6. [Abstract] [Full-text]
12. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
    J Urol, 176(6): 2701-5. [Abstract] [Full-text]
13. Radical prostatectomy after previous prostate surgery: clinical and functional outcomes.
    J Urol, 176(6): 2459-63; discussion 2463. [Abstract] [Full-text]
14. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score?
    J Urol, 176(6): 2453-8; discussion 2458. [Abstract] [Full-text]
15. Age stratified functional outcomes after laparoscopic radical prostatectomy.
    J Urol, 176(6): 2448-52. [Abstract] [Full-text]
16. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.
    J Urol, 176(6): 2443-7. [Abstract] [Full-text]
17. Characteristics of patients with familial versus sporadic prostate cancer.
    J Urol, 176(6): 2438-42; discussion 2442. [Abstract] [Full-text]
18. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.
    J Urol, 176(6): 2432-7. [Abstract] [Full-text]
19. Comparison of methods for calculating prostate specific antigen velocity.
    J Urol, 176(6): 2427-31; discussion 2431. [Abstract] [Full-text]
20. The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate.
    J Urol, 176(6): 2383-5. [Abstract] [Full-text]
21. Management of high risk metastatic prostate cancer: the case for novel therapies.
    J Urol, 176(6): S76-80; discussion S81-2. [Abstract] [Full-text]
22. The case for early chemotherapy for the treatment of metastatic disease.
    J Urol, 176(6): S72-5. [Abstract] [Full-text]
23. The case for secondary hormonal therapies in the chemotherapy age.
    J Urol, 176(6): S66-71. [Abstract] [Full-text]
24. High risk biochemical relapse and the timing of androgen deprivation therapy.
    J Urol, 176(6): S61-5. [Abstract] [Full-text]
25. Management of high risk metastatic prostate cancer: defining risk at the time of initial treatment failure.
    J Urol, 176(6): S57-60; discussion S55-6. [Abstract] [Full-text]
26. Bone related events in high risk prostate cancer.
    J Urol, 176(6): S50-4. [Abstract] [Full-text]
27. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE.
    J Urol, 176(6): S47-9. [Abstract] [Full-text]
28. The case for systemic therapy alone for prostate cancer.
    J Urol, 176(6): S42-6. [Abstract] [Full-text]
29. Management of locally advanced prostate cancer: past, present, future.
    J Urol, 176(6): S34-41. [Abstract] [Full-text]
30. The case for adjuvant therapy for prostate cancer.
    J Urol, 176(6): S30-3. [Abstract] [Full-text]
31. Initial therapy with radical prostatectomy for high risk localized prostate cancer.
    J Urol, 176(6): S27-9; discussion S25-6. [Abstract] [Full-text]
32. Defining high risk prostate cancer--where do we set the bar? A translational science approach to risk stratification.
    J Urol, 176(6): S21-4; discussion S25-6. [Abstract] [Full-text]
33. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.
    J Urol, 176(6): S16-20. [Abstract] [Full-text]
34. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    J Urol, 176(6): S11-5. [Abstract] [Full-text]
35. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues.
    J Cell Physiol, 210(1): 111-21. [Abstract] [Full-text]
36. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section.
    Int J Cancer, 120(1): 170-4. [Abstract] [Full-text]
37. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
    Int J Cancer, 120(1): 160-9. [Abstract] [Full-text]
38. Targeting prostate cancer with radiolabelled bombesins.
    Cancer Imaging, 6: 153-7. [Abstract] [Full-text]
39. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Biochem Biophys Res Commun, 351(3): 658-63. [Abstract] [Full-text]
40. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Cancer Res, 66(22): 11077-83. [Abstract] [Full-text]
41. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor.
    Cancer Res, 66(22): 11047-54. [Abstract] [Full-text]
42. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway.
    Cancer Res, 66(22): 11039-46. [Abstract] [Full-text]
43. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer.
    Cancer Res, 66(22): 10953-8. [Abstract] [Full-text]
44. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
    Cancer Res, 66(22): 10919-28. [Abstract] [Full-text]
45. Phosphorylation by DNA-dependent protein kinase is critical for apoptosis induction by insulin-like growth factor binding protein-3.
    Cancer Res, 66(22): 10878-84. [Abstract] [Full-text]
46. Imaging mitogen-activated protein kinase function in xenograft models of prostate cancer.
    Cancer Res, 66(22): 10778-85. [Abstract] [Full-text]
47. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion.
    Cancer Res, 66(22): 10683-90. [Abstract] [Full-text]
48. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Cancer Res, 66(22): 10658-63. [Abstract] [Full-text]
49. PSA screening among elderly men with limited life expectancies.
    JAMA, 296(19): 2336-42. [Abstract] [Full-text]
50. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
    JAMA, 296(19): 2329-35. [Abstract] [Full-text]
51. Patient and treatment factors associated with complications after prostate brachytherapy.
    J Clin Oncol, 24(33): 5298-304. [Abstract] [Full-text]
52. Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells.
    Oncogene, 25(55): 7311-23. [Abstract] [Full-text]
53. Tumor escape mechanisms in prostate cancer.
    Cancer Immunol Immunother, 56(1): 81-7. [Abstract] [Full-text]
54. Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression.
    Cancer, 107(11): 2628-36. [Abstract] [Full-text]
55. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Cancer, 107(11): 2597-603. [Abstract] [Full-text]
56. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.
    J Clin Oncol, 24(34): 5408-13. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.